Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 1(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00823173Phase 2Completed

Exploratory Study on Topical ESBA105 in Acute Anterior Uveitis

Role: lead

NCT00819572Phase 1Completed

Study of Intra-articular DLX105 Applied to Patients With Severely Painful Osteoarthritis of the Knee

Role: lead

NCT00820014Phase 1Completed

Ocular Biodistribution Study for Topically Applied ESBA105

Role: lead

NCT00671619Phase 1Completed

Study of ESBA105 Eye Drops in Healthy Subjects

Role: lead

All 4 trials loaded